Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-1,238
Closed -$997 4317
2024
Q4
$997 Sell
1,238
-400
-24% -$366 ﹤0.01% 3957
2024
Q3
$1.63K Sell
1,638
-1,888
-54% -$2.59K ﹤0.01% 3830
2024
Q2
$5.46K Buy
+3,526
New +$5.49K ﹤0.01% 3484
2023
Q2
Sell
-2,833
Closed -$2.42K 4090
2023
Q1
$2.42K Buy
2,833
+285
+11% +$311 ﹤0.01% 3709
2022
Q4
$3.31K Buy
2,548
+914
+56% +$1.43K ﹤0.01% 3642
2022
Q3
$3K Sell
1,634
-1,679
-51% -$4.18K ﹤0.01% 3746
2022
Q2
$8K Sell
3,313
-1,203
-27% -$2.88K ﹤0.01% 3434
2022
Q1
$15K Buy
4,516
+1,679
+59% +$5.9K ﹤0.01% 3225
2021
Q4
$13K Buy
2,837
+1,802
+174% +$13.6K ﹤0.01% 3326
2021
Q3
$7K Buy
+1,035
New +$7.6K ﹤0.01% 3557

Other funds holding OCGN

US Bancorp's OCGN Position: Q1 2025 in Review

US Bancorp sold out of Ocugen (OCGN) in Q1 2025, closing a stake of 1,238 shares — an estimated $997 sold.

US Bancorp first reported a position in OCGN in Q3 2021 and held it in 10 quarters. The position peaked at $15K in Q1 2022. 110 funds tracked by Wall St. Rank hold OCGN as of Q1 2025.

  • US Bancorp reported no remaining Ocugen position as of Q1 2025 after selling out during the quarter.
  • US Bancorp sold 1,238 Ocugen shares in Q1 2025, an estimated $997.
  • US Bancorp first reported a position in Ocugen in Q3 2021 and held it in 10 quarters.
  • US Bancorp's Ocugen position peaked at $15K in Q1 2022.
  • 110 funds tracked by Wall St. Rank held Ocugen as of Q1 2025.

Based on US Bancorp's 13F filing for Q1 2025, filed 8 May 2025.